Human blood testing could fast-track mRNA drug development

mRNA-based drugs hold enormous promise — from cancer immunotherapy to rare genetic diseases — but roughly 90% of drug candidates fail in clinical trials, often because animal models don't accurately predict human responses. Researchers at SINTEF think they've found a smarter early-stage screening tool: human whole blood.

The team tested different mRNA-lipid nanoparticle (LNP) formulations in fresh donor blood ex vivo, measuring how immune cells took up the particles and what immune signals were triggered. The results suggest this approach can reliably distinguish high-performing candidates from duds — and flag potentially dangerous allergic reactions — before a single human volunteer is enrolled.

Key Takeaways:

• mRNA must be packaged in lipid nanoparticles (LNPs) to function as a drug; LNP design is critical and highly variable
• Ex vivo human blood testing can complement — not replace — animal studies, offering earlier, more human-relevant data
• The method shows particular promise for in vivo CAR-T therapy, where mRNA is injected to reprogram immune cells directly inside the patient, potentially reducing treatment costs significantly

Why it matters: Better preclinical screening means fewer late-stage failures, lower development costs, and — critically — fewer patients harmed by unpredicted side effects. For therapies like CAR-T, which currently carry substantial costs, this could be a meaningful step toward making cutting-edge treatments more widely accessible.